K Kostev

Summary

Affiliation: IMS Health

Publications

  1. pmc Resource consumption and costs of treatment in patients with type 1 diabetes under intensified conventional therapy under German real-life conditions
    Karel Kostev
    CES LifeLink Epidemiology, IMS HEALTH GmbH and Co OHG, Darmstädter Landstraße 108, Frankfurt am Main, Germany
    J Diabetes Sci Technol 7:736-42. 2013
  2. doi request reprint Frequency of hospitalizations prior to and after conversion to a rebate pharmaceutical in depression patients in Germany
    Karel Kostev
    IMS Health, Frankfurt am Main, Germany
    Int J Clin Pharmacol Ther 51:416-22. 2013
  3. doi request reprint Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany, France, and UK
    Karel Kostev
    IMS Health, Frankfurt, Germany
    Prim Care Diabetes 7:167-71. 2013
  4. doi request reprint Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis
    K Kostev
    IMS Health, Epidemiology, Darmstädter Landstraße 108, 60598 Frankfurt am Main, Germany
    Diabetologia 56:109-11. 2013
  5. doi request reprint Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany
    Karel Kostev
    IMS Health Epidemiology, Darmstädter Landstraße 108, 60598 Frankfurt Main, Germany
    Prim Care Diabetes 6:329-35. 2012
  6. ncbi request reprint Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin
    K Kostev
    IMS HEALTH GmbH and Co, OHG, Frankfurt Main, Germany
    J Wound Care 21:483-4, 486-9. 2012
  7. pmc Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study
    Anna Volodina
    Institute of Public Health, University of Heidelberg, Germany
    BMC Public Health 11:509. 2011
  8. ncbi request reprint The negative impact of rebate contracts on the health care of patients with depression in Germany
    K Kostev
    Center of Excellence Patient Data, IMS HEALTH GmbH and Co OHG, Frankfurt, Germany
    Int J Clin Pharmacol Ther 49:397-402. 2011
  9. doi request reprint Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany
    L Breitscheidel
    IMS HEALTH GmbH and Co, OHG, Munich Frankfurt, Germany
    J Med Econ 15:155-65. 2012
  10. ncbi request reprint Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy
    J Mathes
    IMS HEALTH GmbH and Co OHG, Health Economics and Outcomes Research, Nuremberg, Germany
    Int J Clin Pharmacol Ther 48:173-83. 2010

Collaborators

Detail Information

Publications10

  1. pmc Resource consumption and costs of treatment in patients with type 1 diabetes under intensified conventional therapy under German real-life conditions
    Karel Kostev
    CES LifeLink Epidemiology, IMS HEALTH GmbH and Co OHG, Darmstädter Landstraße 108, Frankfurt am Main, Germany
    J Diabetes Sci Technol 7:736-42. 2013
    ....
  2. doi request reprint Frequency of hospitalizations prior to and after conversion to a rebate pharmaceutical in depression patients in Germany
    Karel Kostev
    IMS Health, Frankfurt am Main, Germany
    Int J Clin Pharmacol Ther 51:416-22. 2013
    ....
  3. doi request reprint Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany, France, and UK
    Karel Kostev
    IMS Health, Frankfurt, Germany
    Prim Care Diabetes 7:167-71. 2013
    ..To investigate if micro- and macrovascular co-morbidity has an influence on the time to insulin initiation in type 2 diabetes patients...
  4. doi request reprint Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis
    K Kostev
    IMS Health, Epidemiology, Darmstädter Landstraße 108, 60598 Frankfurt am Main, Germany
    Diabetologia 56:109-11. 2013
    ..The aim of this study was to estimate the prevalence of and risk factors for diabetic retinopathy in newly diagnosed type 2 diabetes in general practices in the UK...
  5. doi request reprint Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany
    Karel Kostev
    IMS Health Epidemiology, Darmstädter Landstraße 108, 60598 Frankfurt Main, Germany
    Prim Care Diabetes 6:329-35. 2012
    ..To assess the predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany...
  6. ncbi request reprint Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin
    K Kostev
    IMS HEALTH GmbH and Co, OHG, Frankfurt Main, Germany
    J Wound Care 21:483-4, 486-9. 2012
    ..To evaluate the effect of the long-acting basal insulin analog glargine compared with neutral protamine Hagedorn (NPH) insulin on the incidence of diabetic foot ulceration (DFU) in patients with diabetes in Germany...
  7. pmc Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study
    Anna Volodina
    Institute of Public Health, University of Heidelberg, Germany
    BMC Public Health 11:509. 2011
    ..The objective of this study is to investigate drug consumption patterns of ethnic German migrants (Aussiedler) and their current health status...
  8. ncbi request reprint The negative impact of rebate contracts on the health care of patients with depression in Germany
    K Kostev
    Center of Excellence Patient Data, IMS HEALTH GmbH and Co OHG, Frankfurt, Germany
    Int J Clin Pharmacol Ther 49:397-402. 2011
    ..Conclusions: Despite the above limitations this analysis presents a clear association between the initiation of rebate contracts and a negative impact on health care of patients with an antidepressive drug therapy...
  9. doi request reprint Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany
    L Breitscheidel
    IMS HEALTH GmbH and Co, OHG, Munich Frankfurt, Germany
    J Med Econ 15:155-65. 2012
    ....
  10. ncbi request reprint Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy
    J Mathes
    IMS HEALTH GmbH and Co OHG, Health Economics and Outcomes Research, Nuremberg, Germany
    Int J Clin Pharmacol Ther 48:173-83. 2010
    ....